Recent Updates
Recently added Catalysts

Glucophage RM Test

Phase 1

Healthy | Small molecule | Other |Merck KGaA|Last Updated: Dec 29, 2023

Target and mechanism

ModalitySmall molecule

Also known as Glucophage® XR RM Test

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials1
Total Enrollment81

FDA Designations

No designations recorded

Clinical trial landscape

Glucophage RM Test · 1 trial · 1 indication

Phase 1 1
NCT04684420GXR RM (Glucophage® Extended Release Reduced Mass) 500 Milligram (mg) Korea Bioequivalence (BE) StudyHealthy
COMPLETED81 Analytics
PHASE1COMPLETED
GXR RM (Glucophage® Extended Release Reduced Mass) 500 Milligram (mg) Korea Bioequivalence (BE) Study
HealthyUnlock trial analytics

Study Endpoints

Primary Endpoints

Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Metformin
Part 1 (fasted): Pre-dose and 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24 and 32 hours post dose. Part 2 (fed): Pre-dose 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 12, 24 and 32 hours post dose

Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.

Maximum Observed Plasma Concentration (Cmax) of Metformin
Part 1 (fasted): Pre-dose and 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24 and 32 hours post dose. Part 2 (fed): Pre-dose 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 12, 24 and 32 hours post dose

Cmax was obtained directly from the concentration versus time curve.

Secondary Endpoints

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
From Day 1 up to 3 weeks
Number of Participants Taking Concomitant Medications
From Day 1 up to 3 weeks
Number of Participants With Clinically Significant Change From Baseline in Laboratory Values
From Day1 (baseline) up to 3 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeOTHER

Treatment Arms

ArmTypeDescription
First Reference GXR (Fasting), Then Test GXR RM (Fasting)EXPERIMENTALParticipants received a single oral dose of 500 milligram (mg) of reference GXR (Glucophage® Extended Release) tablet on Day 1 in treatment period 1 followed by single oral dose of 500 mg test GXR RM (Reduced Mass) tablet on Day 8 in treatment period 2 under fasting conditions. There was a washout period of 7 days between two treatment period.
First Test GXR RM (Fasting), Then Reference GXR (Fasting)EXPERIMENTALParticipants received a single oral dose of 500 milligrams (mg) of test GXR RM tablet on Day 1 in treatment period 1 followed by single oral dose of 500 mg of reference GXR tablet on Day 8 in treatment period 2 under fasting conditions. There was a washout period of 7 days between two treatment period.
First Reference GXR (Fed), Then Test GXR RM (Fed)EXPERIMENTALParticipants received a single oral dose of 500 milligrams (mg) of reference GXR tablet on Day 1 in treatment period 1 followed by single oral dose of 500 mg of test GXR RM tablet on Day 8 in treatment period 2 under fed conditions. There was a washout period of 7 days between two treatment period.
First Test GXR RM (Fed), Then Reference GXR (Fed)EXPERIMENTALParticipants received a single oral dose of 500 milligrams (mg) of test GXR RM tablet on Day 1 in treatment period 1 followed by single oral dose of 500 mg of reference GXR tablet on Day 8 in treatment period 2 under fed conditions. There was a washout period of 7 days between two treatment period.

Interventions

NameTypeDescription
Glucophage® XR RM TestDRUGParticipants received a single oral dose of 500 mg of test Glucophage® XR RM tablet under fasting or fed conditions.
Glucophage® XR ReferenceDRUGParticipants received a single oral dose of 500 mg of reference Glucophage® XR tablet under fasting or fed conditions.
Unlock Study Design Details

Eligibility Criteria

Age Range19 Years to 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * All values for hematology and biochemistry tests of blood and urinalysis (especially Estimated Glomerular Filtration Rate \[eGFR\] greater than \[\>\] 80 milliliters per minute per 1.73 square meter \[80 ml/min/1.73 m\^2\] and normal Creatinine) within the normal range or show...

Countries:South Korea
Unlock Eligibility Criteria